EMA Recommends Susvimo for Neovascular Age-Related Macular Degeneration
EMA recommends Susvimo, an ocular implant that releases ranibizumab over time, as a new treatment option for adults with stable neovascular age-related macular degeneration.
First Oral IL-23 Receptor Antagonist Recommended for Plaque Psoriasis
EMA recommends Icotyde (icotrokinra), the first oral medicine targeting the interleukin-23 pathway, for moderate-to-severe plaque psoriasis in adults and adolescents.
EMA Fast Tracks Review of Daraxonrasib for Metastatic Pancreatic Cancer
EMA's CHMP starts phased review of daraxonrasib, a medicine for metastatic pancreatic cancer, to accelerate assessment for patients with limited treatment options.
Marketing Authorisation for Tavneos (Avacopan) Recommended for Revocation
CHMP recommends revoking Tavneos' EU marketing authorisation after finding that the pivotal Advocate study data are incorrect and misleading due to GCP breaches.
EMA 2025 Annual Report: Strong Approvals for Human and Veterinary Medicines
EMA's 2025 annual report shows 104 human and 30 veterinary medicines recommended, marking the agency's 30th anniversary.
EMA, AMA and African Regulators Join Forces on Ebola Outbreak Response
EMA's Emergency Task Force collaborates with AMA and African regulators to advance clinical trials and medical countermeasures for the Bundibugyo Ebola outbreak in the DRC and Uganda.
ETF Recommends Updating COVID-19 Vaccines to Target XFG Variant
EMA's Emergency Task Force recommends updating COVID-19 vaccines to target the XFG variant for the 2026/2027 vaccination campaign.
EU recommendations for 2026/2027 seasonal flu vaccine composition
Annual updates to virus strains ensure vaccines stay effective
EMA Recommends First Oral GLP-1 Treatment for Weight Management
EMA recommends first oral GLP-1 (semaglutide) for weight management, offering Wegovy tablets as an alternative to injections.